Gilead Sciences (GILD) EBITDA (2009 - 2026)

Gilead Sciences (GILD) has 18 years of EBITDA data on file, last reported at $2.6 billion in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 15.6% year-over-year to $2.6 billion; the trailing twelve-month figure through Mar 2026 stood at $10.4 billion (up 26.15% YoY), and the FY2025 full-year result was $10.0 billion, up 503.01% from the prior year.
• EBITDA for Q1 2026 stood at $2.6 billion, up from $2.0 billion in the prior quarter.
• Across five years, EBITDA topped out at $3.3 billion in Q3 2025 and bottomed at -$4.3 billion in Q1 2024.
• The 5-year median for EBITDA is $2.2 billion (2025), against an average of $1.7 billion.
• The widest annual swing landed in 2023, when EBITDA soared 765.48%; it then slumped 353.49% in 2024.
• A 5-year view of EBITDA shows it stood at $2.3 billion in 2022, then dropped by 28.89% to $1.6 billion in 2023, then jumped by 52.11% to $2.5 billion in 2024, then retreated by 19.09% to $2.0 billion in 2025, then surged by 30.34% to $2.6 billion in 2026.
• The last three EBITDA figures came in at $2.6 billion (Q1 2026), $2.0 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.

Peer Comparison